Written by: Dr. Akash Chandawarkar, Board Certified Plastic Surgeon, Mirror Plastic Surgery | Last updated: September 9, 2026
Key Takeaways
- Prescription weight loss medications are FDA-approved for adults with BMI ≥30, or BMI ≥27 with weight-related conditions, and work best alongside diet and exercise.
- As of 2026, nine FDA-approved drugs are available. Zepbound delivers the highest average weight loss, while newer oral options like Foundayo and oral Wegovy add convenience.1
- GLP-1 medications outperform older pills and often cause GI side effects. Medical supervision helps manage dosing, monitor complications, and avoid unsafe compounded products.
- Cost and insurance coverage vary widely. Medicare usually excludes weight-loss drugs, while manufacturer savings programs and self-pay options can lower out-of-pocket costs.
- For personalized guidance on choosing a medication and receiving safe, physician-supervised treatment, schedule a consultation at Mirror Plastic Surgery to discuss your options.
FDA-Approved Weight Loss Drugs: The Complete 2026 List
As of April 2026, the FDA has approved nine pharmacologic options for long-term or short-term weight management in adults, along with one prescription medical device (Plenity) and one over-the-counter option (Alli). The table below summarizes each FDA-approved medication, its active ingredient, how it is taken, and the average weight loss reported in pivotal clinical trials.
| Medication (Brand) | Active Ingredient | Administration | Average Weight Loss* |
|---|---|---|---|
| Zepbound | Tirzepatide | Weekly injection | 20.9% at 72 weeks (SURMOUNT-1) |
| Wegovy HD | Semaglutide (7.2 mg) | Weekly injection | ~18.7% at 72 weeks |
| Wegovy (oral) | Semaglutide (25 mg) | Daily tablet | 16.6% at 64 weeks (adherent participants, OASIS 4) |
| Wegovy | Semaglutide (2.4 mg) | Weekly injection | 14.9% at 68 weeks (STEP 1) |
| Foundayo | Orforglipron | Daily tablet | 12.4% at 72 weeks (ATTAIN-1) |
| Saxenda | Liraglutide | Daily injection | 8.0% at 56 weeks (SCALE) |
| Qsymia | Phentermine/Topiramate | Daily capsule | 9.8% at 56 weeks (CONQUER) |
| Contrave | Naltrexone/Bupropion | Twice-daily tablet | 6.1% at 56 weeks (COR-I) |
| Xenical | Orlistat (120 mg) | Capsule with meals | ~3–5% at 1 year |
*Average weight loss from pivotal clinical trials; individual results vary.
Three medications stand out for their novelty and convenience. Foundayo (orforglipron), approved April 1, 2026, is the first non-peptide oral GLP-1 and can be taken once daily with or without food at any time of day. This flexibility offers a meaningful convenience advantage over other oral options.
Oral Wegovy (semaglutide 25 mg tablet), approved December 22, 2025, is the first oral GLP-1 approved specifically for chronic weight management. It must be taken on an empty stomach with up to 4 oz of water, then you wait at least 30 minutes before food or other medications.
Wegovy HD (semaglutide 7.2 mg), approved March 19, 2026, is indicated for adults who have already tolerated the standard 2.4 mg dose for at least four weeks. It offers additional weight reduction beyond the standard dose.
Additional options include short-term phentermine (Adipex-P), FDA-approved for up to 12 weeks, and setmelanotide (Imcivree) for rare genetic obesity disorders. Plenity is a prescription medical device, not a drug, that expands in the stomach to promote fullness.
Most Effective Prescription Weight Loss Medications In 2026
In the head-to-head SURMOUNT-5 trial published in the New England Journal of Medicine, Zepbound (tirzepatide) produced a mean weight reduction of 20.2% at 72 weeks compared with 13.7% for Wegovy (semaglutide).1 This result makes Zepbound the most effective FDA-approved weight loss medication currently on the U.S. market.
Across pivotal trials, GLP-1 and dual GIP/GLP-1 medications sit at the top of the efficacy range, followed by combination oral pills, then orlistat. The table above shows the specific percentages for each drug so you can compare options side by side.
Effectiveness still varies by individual, and all medications work as adjuncts to lifestyle changes. Most weight loss occurs within the first six months. If a patient has not lost at least 5% of starting weight after 12 weeks on the full dose, the healthcare professional will likely recommend stopping the medication or adjusting the treatment plan.
Discuss your medication options with Ellie to match clinical trial data with your health profile, goals, and lifestyle.
How GLP-1 Medications Compare To Older Weight Loss Pills
GLP-1 and dual GIP/GLP-1 receptor agonists (Wegovy, Zepbound, Saxenda, Foundayo) mimic hormones that regulate appetite, slow stomach emptying, and enhance insulin secretion. They produce the largest average weight loss, typically 8–21% of body weight.
Several GLP-1s also carry additional FDA-approved benefits. Wegovy reduces major cardiovascular events by 20% relative risk reduction in the SELECT trial, and Zepbound is approved for moderate-to-severe obstructive sleep apnea in adults with obesity.1
Older oral medications work through distinct mechanisms and generally produce more modest results:
- Qsymia (phentermine/topiramate): Combines a stimulant appetite suppressant with an anticonvulsant that reduces cravings, producing about 9–10% weight loss.
- Contrave (naltrexone/bupropion): Targets brain reward pathways and may help with emotional eating, producing about 5–6% weight loss.
- Xenical (orlistat): Blocks absorption of about 30% of dietary fat in the gut, producing about 3–5% weight loss and often causing GI side effects with high-fat meals.
- Phentermine alone: The oldest and cheapest option, FDA-approved only for short-term use up to 12 weeks.
The key differences between drug classes fall into four main areas:
- Efficacy: GLP-1s produce roughly 2–4 times greater average weight loss than older oral pills.1
- Administration: Most GLP-1s are injections, except oral Wegovy and Foundayo. Older options are pills.
- Side effect profiles: GLP-1s often cause GI symptoms such as nausea, vomiting, and diarrhea. Qsymia can cause dry mouth and insomnia. Contrave can raise blood pressure. Xenical commonly causes oily stools.
- Cardiovascular benefits: Wegovy has proven heart protection in the SELECT trial. No older weight loss drug carries this indication.
Side Effects Of Prescription Weight Loss Drugs
GLP-1 and dual GIP/GLP-1 medications (Wegovy, Zepbound, Saxenda, Foundayo):
- Common: Nausea affects about 25–44% of users, along with diarrhea, vomiting, constipation, and abdominal pain. These effects are dose-dependent and typically peak during the first 16–20 weeks of dose escalation.
- Serious (rare): Pancreatitis, gallbladder disease, and acute kidney injury from dehydration. All carry an FDA boxed warning for thyroid C-cell tumors based on rodent studies and are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
- Muscle loss concern: Studies suggest 25–39% of total weight lost on GLP-1s comes from lean mass. Clinicians now recommend resistance training and at least 30 grams of protein per meal during active treatment.
Qsymia (phentermine/topiramate): Dry mouth, tingling (paresthesia), insomnia, and constipation are common. Topiramate can cause birth defects, so women of childbearing age need negative pregnancy tests and effective contraception. Qsymia is contraindicated in glaucoma and hyperthyroidism.
Contrave (naltrexone/bupropion): Nausea, headache, and constipation are frequent. Contrave carries an FDA boxed warning for suicidal thoughts and behaviors related to bupropion and is contraindicated with opioid use, seizure disorders, and uncontrolled hypertension.
Compounded GLP-1 Products: The FDA has received over 1,100 adverse event reports tied to compounded semaglutide and tirzepatide, including hospitalizations from dosing errors. These products are not FDA-approved and do not undergo the same premarket review for safety, efficacy, or quality. Careful medical supervision and trusted sourcing are critical if compounded options enter the conversation.
Costs And Coverage For Prescription Weight Loss Medications
List prices for weight loss medications often differ sharply from what patients actually pay. The table below reflects publicly available pricing data as of mid-2026.
| Medication | List Price (Monthly) | Self-Pay / Direct Options | Insurance Coverage |
|---|---|---|---|
| Wegovy | List price available via manufacturer | Direct-pay options available | Coverage varies by employer plan |
| Zepbound | List price available via manufacturer | Direct-pay options available | Coverage varies by plan |
| Foundayo | List price available via manufacturer | Direct-pay options available | Savings programs may apply |
| Saxenda | List price available via manufacturer | Generic authorized version available | Limited |
| Qsymia | List price available via manufacturer | Generic available | Varies by plan |
| Contrave | List price available via manufacturer | Generic components available | Varies by plan |
| Xenical | List price available via manufacturer | OTC Alli available | Rarely covered |
Several coverage dynamics shape what you actually pay at the pharmacy counter:
- Medicare: Federal law prohibits Medicare Part D coverage of medications used solely for weight loss. However, a Medicare GLP-1 Bridge pilot program running July 2026 through December 2027 provides Foundayo, Wegovy, and Zepbound KwikPen to eligible Part D beneficiaries for a set monthly amount.
- Medicaid: Only 13 state Medicaid programs cover GLP-1s for obesity treatment as of January 2026, and several states ended coverage in 2026.
- Employer plans: A portion of large employers cover GLP-1s for both diabetes and weight loss, similar to 2025 levels.
- Manufacturer savings programs: Copay cards exclude Medicare and Medicaid beneficiaries and do not activate if insurance denies prior authorization, which can leave patients paying negotiated rates even with insurance.
How To Choose The Right Prescription Weight Loss Medication
The American College of Physicians’ 2026 living guideline recommends semaglutide and tirzepatide as first-line pharmacologic options for adults with obesity (BMI ≥30) and for adults with overweight (BMI ≥27) plus at least one comorbidity. Liraglutide is second-line, phentermine-topiramate third-line, and naltrexone-bupropion fourth-line.
Medication selection still needs to match your specific health picture and preferences. Key factors include:
- Your BMI and comorbidities: Wegovy reduces cardiovascular events, and Zepbound is approved for obstructive sleep apnea. Aligning the medication with your conditions can increase overall benefit.
- Injection vs pill preference: If you dislike injections, oral options now exist. Oral Wegovy requires fasting, while Foundayo has no food restrictions.
- Weight loss goals: For maximum weight loss in the 15–20% range, Zepbound or Wegovy HD offer the strongest trial results. For a 5–10% reduction that still improves health markers, older oral medications may be enough.1
- Side effect tolerance: GLP-1s often cause GI symptoms. Qsymia can cause dry mouth and carries pregnancy-related risks. Contrave may raise blood pressure.
- Insurance and access: Check your formulary early. If your plan excludes GLP-1s, manufacturer savings programs or self-pay options may still make treatment possible.
- Muscle preservation: If maintaining lean mass is a priority, especially for older adults, discuss resistance training and protein intake with your provider.
Top 3 Weight Loss Drugs In 2026 (By Trial Efficacy）
- Zepbound (tirzepatide)
- Wegovy HD (semaglutide 7.2 mg)
- Oral Wegovy (semaglutide 25 mg)
Meet with Ellie and Dr. Akash so they can review your labs, health history, and goals and recommend the right medication or peptide protocol for your physiology.
The Role Of Medical Supervision In Weight Loss Treatment
Medical supervision forms the backbone of safe and effective prescription weight loss treatment. Physician oversight shapes dosing, monitors your response, and protects you from unsafe products.
Several elements work together during supervised care:
- Proper dosing and titration: GLP-1s require gradual dose escalation over weeks to minimize GI side effects. A physician tracks your response and adjusts the schedule.
- Monitoring for complications: Regular follow-ups help catch rare but serious issues such as pancreatitis, gallbladder disease, or kidney injury early, when intervention works best.
- Avoiding unsafe products: The compounded product risks discussed earlier highlight why you need a trusted source. A physician steers you away from unregulated “research use only” vials that may contain inaccurate doses, contamination, or no active ingredient.
- Personalized care: A qualified provider reviews your medical history, orders labs such as thyroid, liver, kidney, diabetes markers, and hormone panels, then designs a protocol tailored to your physiology.
This is where Mirror Plastic Surgery stands out. Under the leadership of Dr. Akash Chandawarkar, a Harvard-educated, Johns Hopkins-trained, board-certified plastic surgeon, the practice offers concierge-level medical supervision for weight management.
Dr. Akash spends up to an hour in consultation, reviews comprehensive lab panels, and designs personalized protocols that may include FDA-approved GLP-1 medications or advanced peptide therapies such as GLP-3R compounding, a newer-generation peptide similar to GLP-1 that early reports suggest may cause fewer GI side effects and less muscle wasting.
Mirror Plastic Surgery provides true one-on-one care with direct physician access, quality-sourced medications, and ongoing support throughout your treatment journey.
Common Misconceptions About Prescription Weight Loss Medications
“These drugs are a quick fix.” Prescription medications support long-term weight management and work best alongside nutrition, movement, and sleep changes.
1 Results may vary from person to person. Editorial content, before and after images, and patient testimonials do not constitute a guarantee of specific results.
Peptide therapy is intended for wellness and optimization purposes and is not prescribed to diagnose, treat, cure, or prevent disease unless specifically stated. Many peptides are not FDA-approved and may be used off-label. Some have limited long-term safety data, with a potential for unknown risks, complications, or desensitization with prolonged use.
